Inflammatory ResponseNCT05573438
Acute Inflammatory and Metabolic Effect of High Fructose Intake
A study testing Group fructose, Group Sucrose and Group Glucose in people with Inflammatory Response and Metabolic Disturbance, run by Adaliene Versiani M. Ferreira.
Trial summary
Fructose consumption is associated with the development of metabolic diseases and low-grade inflammation. However, the acute effect of a single meal rich in fructose on the metabolic and inflammatory response is not fully understood. Read more about this study
- Who is it for?
- Ages 20 to 50 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Inflammatory Response, Metabolic Disturbance
- What is being tested?
- Group fructose, Group Sucrose and Group Glucose
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 22 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2015to 30 Nov 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 50 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Women aged
- 20 and 47 years
- body mass index (BMI) from 18.50 to 24.99 kg/m²
Who cannot join
- chronic diseases, such as DM, chronic renal failure (CRF), cardiovascular or hepatic diseases, acute inflammatory or autoimmune diseases;
- participants with glycemia > 99 mg/dL;
- triglycerides > 200 mg/dL;
- prior bariatric surgery for weight loss;
- people who were taking medication for thyroid disorders, dyslipidemia, insulin sensitivity or DM, CRF, cardiovascular and hepatic diseases, inflammation and/or infection, immunosuppressive and weight loss;
- smokers or people who drink more than two doses of alcohol a day (28g of pure alcohol); and (vii) pregnancy or breast-feeding.
About this study
Official title: Acute Inflammatory and Metabolic Effect of High Fructose Intake in Normal Weight Women: Double Blind, Randomized Crossover Study.
Fructose consumption is associated with the development of metabolic diseases and low-grade inflammation. However, the acute effect of a single meal rich in fructose on the metabolic and inflammatory response is not fully understood. This study will to evaluate the acute metabolic and inflammatory effect caused by a meal containing fructose overload. This will be a three-arm crossover, randomized, double-blind clinical trial.
Participants will undergo the three interventions for random order: (i) standardized meal plus sucrose overload; (ii) standardized meal plus glucose overload; (iii) standardized meal plus fructose overload. During the washout period (7 to 21 days), the subjects will instructed to maintain their usual eating behavior and physical activity.
Read more
On the day of each intervention, participants will to the outpatient clinic in the morning after an overnight fast. Anthropometric data (weight, height, and waist circumference) will collected. Body composition will evaluated using bioimpedance (Quantum® apparatus, RJM Systems, Michigan) and blood pressure and heart rate (digital monitor, model HEM705CP®, Omron) will measured after 30 minutes of rest.
A catheter with a three-way stopcock will inserted into the arm of the volunteers. Blood samples (5mL) will collected after overnight fasting (baseline) and 30, 60, 120, and 240 minutes after the standardized meal containing sucrose or glucose or fructose overload. Participants will remain seated throughout the evaluation period. Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with similar amounts of different carbohydrates (sucrose, glucose, or fructose) in each intervention. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor plus 10% referring to the thermal effect of food. The meal will consiste of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose or glucose or fructose).
Serum levels of glucose, triglycerides, total cholesterol, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) will be measured by colorimetric enzymatic test. Serum levels of adiponectin, leptin, resistin and TNF will be measured by Enzyme Linked ImmuneSorbent Assay (ELISA). Serum levels of IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, IFN-γ and eotaxin will be obtained by the Cytometric Bead Array (CBA).
Read the detailed description
This will be a three-arm crossover, randomized, double-blind clinical trial performed at the Alpha Institute of Gastroenterology of the Hospital das Clínicas (Belo Horizonte, MG, Brazil). All experimental procedures will be conducted according to the guidelines laid down in the Declaration of Helsinki. The research protocol was approved by the Institutional Review Board of the Universidade Federal de Minas Gerais (CAAE: 21852314.7.0000.5149). All volunteers will signed the informed consent prior to the start of the study.
Sample The sample size of 17 subjects was calculated considering the minimum number of participants to detect a difference of at least 11 mg/dL in the levels of triglycerides, 1.2 ng/mL in adiponectin and 1.9 pg/mL in TNF (pilot study) before and after the intake of a single meal containing a fructose overload, 95% confidence interval and statistical power of the 80%.
Study design Each participant will in three visits with washout period between 7 and 21 days. At each visit, the participant will pass by a different intervention. Three interventions will curr in random order: (i) standardized meal plus sucrose overload; (ii) standardized meal plus glucose overload; (iii) standardized meal plus fructose overload. During the washout period, the subjects will instructed to maintain their usual eating behavior and physical activity. Participants will instructed to avoid consuming caffeine and alcoholic beverages and perform intense physical activity within 24 hours before each visit.
On the day of each intervention, participants will go to the outpatient clinic in the morning after an overnight fast. Anthropometric data (weight, height, and waist circumference) will collected. Body composition will evaluated using bioimpedance (Quantum® apparatus, RJM Systems, Michigan) and blood pressure and heart rate (digital monitor, model HEM705CP®, Omron) will measured after 30 minutes of rest.
A catheter with a three-way stopcock will inserted into the arm of the volunteers. Blood samples (5mL) will collected after overnight fasting (baseline) and 30, 60, 120, and 240 minutes after the standardized meal containing sucrose or glucose or fructose overload. Participants remained seated throughout the evaluation period.
Intervention Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with similar amounts of different carbohydrates (sucrose, glucose, or fructose) in each intervention. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor plus 10% referring to the thermal effect of food. The meal will consiste of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose or glucose or fructose). The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
The amount of refined offered carbohydrates to the participants (18 - 25g in a single meal) will considered an overload since the World Health Organization and the National Center for Chronic Disease Prevention and Health Promotion recommend that the consumption of added sugars should not exceed 10% of the total daily calories. For example, in a 2.000 caloric diet, no more than 200 calories should come from added sugars (about 12 teaspoons). In addition, several authors who investigated short- and long-term (≥ 3 weeks) fructose consumption in metabolic and inflammatory biomarkers offered 25% of total energy expenditure (GET) in the form of sucrose, glucose, fructose or high fructose corn syrup per day. On the other hand, the amount of these carbohydrates offered in the present study is part of the eating routine of many individuals (e.g., 200mL of regular soda contains 21 grams of sucrose).
Blood analysis Serum levels of glucose, triglycerides, total cholesterol, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) will measured by colorimetric enzymatic test (Bioclin®, Belo Horizonte, MG, Brazil). Serum levels of adiponectin, leptin, resistin and TNF will measured by Enzyme Linked ImmuneSorbent Assay (ELISA) following the manufacturer's instructions (R\&D Systems®). Serum levels of IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, IFN-γ and eotaxin will obtained by the Cytometric Bead Array (CBA) method (BD Bioscience, San Diego, CA, USA) in flow cytometry. Collected blood will diluted in Turk's solution. The number of total white blood cell will obtained using a Neubauer chamber (×40 objective).
Statistical Analyses All quantitative variables will present as mean ± standard error (SEM). The normality of the quantitative variables will tested through the Shapiro-Wilk test. Student's t Simple and Mann-Whitney tests will allow comparisons between the initial characteristics of those who completed the study and those who did not, and between volunteers who will participate in the sub-sample and those who not. To compare the anthropometric and clinical characteristics between baseline and the subsequent assessments, we will use the ANOVA test for repeated measures 1-factor or Kruskal-Wallis according to the normality followed by Bonferroni post-test. Postprandial metabolic and inflammatory markers will compared by the Generalized Equation of Estimates (GEE) model to evaluate the effect of group allocation (carbohydrate type), time and adjusting for time-group effect (interaction). The variables will treated with the connection range function and the correlation matrix will the covariance of an unstructured and robust estimator. The Bonferroni post-test will identifie the presence of signifcant effects. Significance will set at P < 0.05. The data will analysed using the Statistical Package for the Social Sciences (SPSS) software version 20 and GraphPad Prism version 5.0.
- Conditions
- Inflammatory Response, Metabolic Disturbance
- Being tested
- Group fructose, Group Sucrose, Group Glucose
- Keywords
- Fructose, Postprandial Period, Inflammation, Metabolism
- Medical subject headings
- Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Group fructoseOther
Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with fructose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of fructose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
Group SucroseOther
Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with sucrose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
Group GlucoseOther
Also called Placebo Comparator
Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with glucose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of glucose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
| Study group | Role | What they receive |
|---|---|---|
| Fructose | Experimental | Participants received a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with fructose. The meals provided 25% of the energy requirements. The meal consisted of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of fructose). Receives: Other: Group fructose |
| Sucrose | Experimental | Participants received a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with sucrose. The meals provided 25% of the energy requirements. The meal consisted of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose). Receives: Other: Group Sucrose |
| Glucose | Placebo comparator | Participants received a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with glucose. The meals provided 25% of the energy requirements. The meal consisted of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of glucose). Receives: Other: Group Glucose |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in serum levels of triglycerides
Triglycerides (ml/dL)
Measured: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of adiponectin
Adiponectin (pg/dL)
Measured: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of tumor necrosis factor
Tumor necrosis factor (pg/dL)
Measured: Change from Baseline serum level at 240 minutes postprandial.
Secondary outcomes (14)
Changes in serum levels of interleukin-2
Interleukin-2 (pg/dL)
Measured: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of interleukin-4
Interleukin-4 (pg/dL)
Measured: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of interleukin-5
Interleukin-5 (pg/dL)
Measured: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of interleukin-6
Interleukin-6 (pg/dL)
Measured: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of interleukin-10
Interleukin-10 (pg/dL)
Measured: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of interleukin-17
Interleukin-17 (pg/dL)
Measured: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of interferon gamma
Interferon gamma (pg/dL)
Measured: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of ofeotaxin
Ofeotaxin (pg/dL)
Measured: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of glucose
Glucose (mg/dL)
Measured: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of cholesterol
Cholesterol (mg/dL)
Measured: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of Aspartate aminotransferase
Aspartate aminotransferase (U/L)
Measured: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of Alanine aminotransferase
Aspartate aminotransferase (U/L)
Measured: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of Leptin
Leptin (pg/dL)
Measured: Change from Baseline serum level at 240 minutes postprandial.
Change in metabolic profile
Resistin (pg/mL)
Measured: Change from Baseline serum level at 240 minutes postprandial.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Oct 2022
- Study start1 Jan 2015
- Primary completion30 Nov 2017
- Study completion30 Nov 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Inflammatory ResponseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- This will be a three-arm crossover, randomized, double-blind clinical trial.
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 22 participants (actual)
Sponsor and investigators
- Lead sponsor
- Adaliene Versiani M. Ferreira
- Sponsor type
- University, hospital or other
- Collaborators
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior., Fundação de Amparo à Pesquisa do estado de Minas Gerais, Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Responsible party
- Sponsor-investigator, Adaliene Versiani M. Ferreira, Federal University of Minas Gerais
- Investigators
- Adaliene VM Ferreira, PhD, Principal investigator, Federal University of Minas Gerais
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05573438
- Sponsor's protocol ID
- CAAE: 21852314.7.0000.5149
- Status last verified
- Oct 2022
- First submitted
- 22 Sep 2022
- Last updated
- 10 Oct 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Rodrigues AMDS, Martins LB, Fagundes GBP, Tibaes JRB, Amaral MHA, Vieira ELM, Oliveira MC, Correia MITD, Ferreira AVM. Acute inflammatory and metabolic effect of high fructose intake in normal-weight women: A randomized, double-masked, crossover trial. Nutrition. 2025 Jan;129:112602. doi: 10.1016/j.nut.2024.112602. Epub 2024 Oct 9.
PubMed 39442382
Study at a glance
From the registry record, last updated by the sponsor on 10 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Acute Inflammatory and Metabolic Effect of High Fructose Intake in Normal Weight Women: Double Blind, Randomized Crossover Study.
- ClinicalTrials.gov ID
- NCT05573438
- Acronym / sponsor ID
- CAAE: 21852314.7.0000.5149
- Conditions
- Inflammatory Response, Metabolic Disturbance
- Keywords
- Fructose, Postprandial Period, Inflammation, Metabolism
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 22 participants (actual)
- Lead sponsor
- Adaliene Versiani M. FerreiraUniversity, hospital or other
- Collaborators
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior., Fundação de Amparo à Pesquisa do estado de Minas Gerais, Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Study start
- 1 Jan 2015 (actual)
- Primary completion
- 30 Nov 2017 (actual)
- Study completion
- 30 Nov 2017 (actual)
- First posted
- 10 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Fructose consumption is associated with the development of metabolic diseases and low-grade inflammation. However, the acute effect of a single meal rich in fructose on the metabolic and inflammatory response is not fully understood. This study will to evaluate the acute metabolic and inflammatory effect caused by a meal containing fructose overload. This will be a three-arm crossover, randomized, double-blind clinical trial.
Participants will undergo the three interventions for random order: (i) standardized meal plus sucrose overload; (ii) standardized meal plus glucose overload; (iii) standardized meal plus fructose overload. During the washout period (7 to 21 days), the subjects will instructed to maintain their usual eating behavior and physical activity.
On the day of each intervention, participants will to the outpatient clinic in the morning after an overnight fast. Anthropometric data (weight, height, and waist circumference) will collected. Body composition will evaluated using bioimpedance (Quantum® apparatus, RJM Systems, Michigan) and blood pressure and heart rate (digital monitor, model HEM705CP®, Omron) will measured after 30 minutes of rest.
A catheter with a three-way stopcock will inserted into the arm of the volunteers. Blood samples (5mL) will collected after overnight fasting (baseline) and 30, 60, 120, and 240 minutes after the standardized meal containing sucrose or glucose or fructose overload. Participants will remain seated throughout the evaluation period. Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with similar amounts of different carbohydrates (sucrose, glucose, or fructose) in each intervention. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor plus 10% referring to the thermal effect of food. The meal will consiste of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose or glucose or fructose).
Serum levels of glucose, triglycerides, total cholesterol, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) will be measured by colorimetric enzymatic test. Serum levels of adiponectin, leptin, resistin and TNF will be measured by Enzyme Linked ImmuneSorbent Assay (ELISA). Serum levels of IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, IFN-γ and eotaxin will be obtained by the Cytometric Bead Array (CBA).
Detailed description
This will be a three-arm crossover, randomized, double-blind clinical trial performed at the Alpha Institute of Gastroenterology of the Hospital das Clínicas (Belo Horizonte, MG, Brazil). All experimental procedures will be conducted according to the guidelines laid down in the Declaration of Helsinki. The research protocol was approved by the Institutional Review Board of the Universidade Federal de Minas Gerais (CAAE: 21852314.7.0000.5149). All volunteers will signed the informed consent prior to the start of the study.
Sample The sample size of 17 subjects was calculated considering the minimum number of participants to detect a difference of at least 11 mg/dL in the levels of triglycerides, 1.2 ng/mL in adiponectin and 1.9 pg/mL in TNF (pilot study) before and after the intake of a single meal containing a fructose overload, 95% confidence interval and statistical power of the 80%.
Study design Each participant will in three visits with washout period between 7 and 21 days. At each visit, the participant will pass by a different intervention. Three interventions will curr in random order: (i) standardized meal plus sucrose overload; (ii) standardized meal plus glucose overload; (iii) standardized meal plus fructose overload. During the washout period, the subjects will instructed to maintain their usual eating behavior and physical activity. Participants will instructed to avoid consuming caffeine and alcoholic beverages and perform intense physical activity within 24 hours before each visit.
On the day of each intervention, participants will go to the outpatient clinic in the morning after an overnight fast. Anthropometric data (weight, height, and waist circumference) will collected. Body composition will evaluated using bioimpedance (Quantum® apparatus, RJM Systems, Michigan) and blood pressure and heart rate (digital monitor, model HEM705CP®, Omron) will measured after 30 minutes of rest.
A catheter with a three-way stopcock will inserted into the arm of the volunteers. Blood samples (5mL) will collected after overnight fasting (baseline) and 30, 60, 120, and 240 minutes after the standardized meal containing sucrose or glucose or fructose overload. Participants remained seated throughout the evaluation period.
Intervention Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with similar amounts of different carbohydrates (sucrose, glucose, or fructose) in each intervention. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor plus 10% referring to the thermal effect of food. The meal will consiste of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose or glucose or fructose). The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
The amount of refined offered carbohydrates to the participants (18 - 25g in a single meal) will considered an overload since the World Health Organization and the National Center for Chronic Disease Prevention and Health Promotion recommend that the consumption of added sugars should not exceed 10% of the total daily calories. For example, in a 2.000 caloric diet, no more than 200 calories should come from added sugars (about 12 teaspoons). In addition, several authors who investigated short- and long-term (≥ 3 weeks) fructose consumption in metabolic and inflammatory biomarkers offered 25% of total energy expenditure (GET) in the form of sucrose, glucose, fructose or high fructose corn syrup per day. On the other hand, the amount of these carbohydrates offered in the present study is part of the eating routine of many individuals (e.g., 200mL of regular soda contains 21 grams of sucrose).
Blood analysis Serum levels of glucose, triglycerides, total cholesterol, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) will measured by colorimetric enzymatic test (Bioclin®, Belo Horizonte, MG, Brazil). Serum levels of adiponectin, leptin, resistin and TNF will measured by Enzyme Linked ImmuneSorbent Assay (ELISA) following the manufacturer's instructions (R\&D Systems®). Serum levels of IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, IFN-γ and eotaxin will obtained by the Cytometric Bead Array (CBA) method (BD Bioscience, San Diego, CA, USA) in flow cytometry. Collected blood will diluted in Turk's solution. The number of total white blood cell will obtained using a Neubauer chamber (×40 objective).
Statistical Analyses All quantitative variables will present as mean ± standard error (SEM). The normality of the quantitative variables will tested through the Shapiro-Wilk test. Student's t Simple and Mann-Whitney tests will allow comparisons between the initial characteristics of those who completed the study and those who did not, and between volunteers who will participate in the sub-sample and those who not. To compare the anthropometric and clinical characteristics between baseline and the subsequent assessments, we will use the ANOVA test for repeated measures 1-factor or Kruskal-Wallis according to the normality followed by Bonferroni post-test. Postprandial metabolic and inflammatory markers will compared by the Generalized Equation of Estimates (GEE) model to evaluate the effect of group allocation (carbohydrate type), time and adjusting for time-group effect (interaction). The variables will treated with the connection range function and the correlation matrix will the covariance of an unstructured and robust estimator. The Bonferroni post-test will identifie the presence of signifcant effects. Significance will set at P < 0.05. The data will analysed using the Statistical Package for the Social Sciences (SPSS) software version 20 and GraphPad Prism version 5.0.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- This will be a three-arm crossover, randomized, double-blind clinical trial.
| Arm | Type | Receives |
|---|---|---|
| Fructose | Experimental | Other: Group fructoseParticipants received a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with fructose. The meals provided 25% of the energy requirements. The meal consisted of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of fructose). |
| Sucrose | Experimental | Other: Group SucroseParticipants received a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with sucrose. The meals provided 25% of the energy requirements. The meal consisted of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose). |
| Glucose | Placebo comparator | Other: Group GlucoseParticipants received a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with glucose. The meals provided 25% of the energy requirements. The meal consisted of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of glucose). |
Who may qualify
- Ages
- 20 to 50 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Women aged
- 20 and 47 years
- body mass index (BMI) from 18.50 to 24.99 kg/m²
Key exclusion criteria (6 listed)
- chronic diseases, such as DM, chronic renal failure (CRF), cardiovascular or hepatic diseases, acute inflammatory or autoimmune diseases;
- participants with glycemia > 99 mg/dL;
- triglycerides > 200 mg/dL;
- prior bariatric surgery for weight loss;
- people who were taking medication for thyroid disorders, dyslipidemia, insulin sensitivity or DM, CRF, cardiovascular and hepatic diseases, inflammation and/or infection, immunosuppressive and weight loss;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Group fructoseParticipants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with fructose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of fructose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers. | Other | Fructose |
| Group SucroseParticipants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with sucrose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers. | Other | Sucrose |
| Group GlucoseAlso: Placebo ComparatorParticipants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with glucose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of glucose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers. | Other | Glucose |
Primary outcome
Changes in serum levels of triglycerides
Time frame: Change from Baseline serum level at 240 minutes postprandial.
Triglycerides (ml/dL)
Changes in serum levels of adiponectin
Time frame: Change from Baseline serum level at 240 minutes postprandial.
Adiponectin (pg/dL)
Changes in serum levels of tumor necrosis factor
Time frame: Change from Baseline serum level at 240 minutes postprandial.
Tumor necrosis factor (pg/dL)
14 secondary outcomes
Changes in serum levels of interleukin-2
Time frame: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of interleukin-4
Time frame: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of interleukin-5
Time frame: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of interleukin-6
Time frame: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of interleukin-10
Time frame: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of interleukin-17
Time frame: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of interferon gamma
Time frame: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of ofeotaxin
Time frame: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of glucose
Time frame: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of cholesterol
Time frame: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of Aspartate aminotransferase
Time frame: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of Alanine aminotransferase
Time frame: Change from Baseline serum level at 240 minutes postprandial.
Changes in serum levels of Leptin
Time frame: Change from Baseline serum level at 240 minutes postprandial.
Change in metabolic profile
Time frame: Change from Baseline serum level at 240 minutes postprandial.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Oct 2022.
- Derived from this study: PubMed 39442382Rodrigues AMDS, Martins LB, Fagundes GBP, Tibaes JRB, Amaral MHA, Vieira ELM, Oliveira MC, Correia MITD, Ferreira AVM. Acute inflammatory and metabolic effect of high fructose intake in normal-weight women: A randomized, double-masked, crossover trial. Nutrition. 2025 Jan;129:112602. doi: 10.1016/j.nut.2024.112602. Epub 2024 Oct 9.
- Individual participant dataSharing planned: No
Related trials for Inflammatory Response
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Recruiting
Change in Platelet Lipid Metabolism and Procoagulant Phenotype Induced by Cardiopulmonary Bypass. Impact on Postoperative Inflammatory Response and Bleeding Complications During Cardiac Surgery.
Cardiac Surgery, Cardiopulmonary Bypass
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Adaliene VM Ferreira, PhD principal investigator
Federal University of Minas Gerais
Questions about this trial
What is this clinical trial studying?
A study testing Group fructose, Group Sucrose and Group Glucose in people with Inflammatory Response and Metabolic Disturbance, run by Adaliene Versiani M. Ferreira.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in serum levels of triglycerides (time frame: Change from Baseline serum level at 240 minutes postprandial.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05573438, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Oct 2022.